Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

GS-5806

Single dose, oral liquid, .5 mL/kg

DRUG

Placebo

Single dose, oral liquid, .5 mL/kg

Trial Locations (9)

3220

Geelong Hospital, Geelong

Unknown

Monash Medical Center, Clayton

Queensland Children's Medical Research Unit, Herston

Royal Hobart Hospital, Hobart

Women's and Children's Hospital Adelaide, North Adelaide

Royal Children's Hospital, Parkville

Sydney Children's Hospital, Randwick

Princess Margaret Hospital for Children, Subiaco

Westmead Children's Hospital, Westmead

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT01797419 - Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV) | Biotech Hunter | Biotech Hunter